Search results

ANSTO's Chief Nuclear Officer shares insights on the safe management of Australia's nuclear waste.

A large international team has developed a new compound that showed strong activity against HIV, including some drug-resistant variants.

A team of scientists from The Australian National University (ANU) has discovered how a powerful “weapon” used by many fungal pathogens enables them to cause disease in major food crops such as rice and corn

Padstow North and Caringbah North selected as winners of ANSTO's Top Coder competition.

ANSTO plays a leading role in measuring and characterising fine particles from a range of locations around Australia and internationally.

ANSTO is celebrating the official opening of HIFAR, Australia’s first nuclear reactor, sixty-five years ago.

ANSTO facilitating coordinated effort to find the nexus that leads to chronic kidney disease of unknown origin

In 2023 we’re celebrating the 70th Anniversary since Australia began developing our nation’s Australia’s nuclear capabilities.

ANSTO researchers have demonstrated longstanding expertise in the study of nuclear fuel and radioactive waste with two recent journal articles in a special issue of Frontiers of Chemistry.

ANSTO User Meeting 2021 - Speakers

The Nobel Prizes for Physics, Chemistry and Medicine have been announced. 

A desire to give people around the world greater access to the benefits of nuclear medicine is behind Robert Raposio and his research into producing radioisotopes in more efficient, cheaper and sustainable ways.

ANSTO commenced an aerosol sampling program thirty years ago this week to characterise these pollutants and ultimately, identify their sources, which has taken it to the forefront of environmental monitoring of this type in Australia and the region.

Scientists from Monash, ANSTo and China have developed an ultra-thin membrane that could separate harmful ions from water or capture gases.

The High Performance Macromolecular Crystallography beamline will enable the study of very small (sub-5 micrometre) or weakly diffracting crystals, providing a state-of-the-art high-throughput facility for researchers. MX3 will be able to study the structures of large proteins and protein complexes for virology, drug design and industrial applications via goniometer mounted crystals, in-tray screening, or via serial crystallography methods.